244
Views
21
CrossRef citations to date
0
Altmetric
Review

Palmatine as an Agent Against Metabolic Syndrome and Its Related Complications: A Review

ORCID Icon, ORCID Icon & ORCID Icon
Pages 4963-4974 | Published online: 17 Nov 2020

Abstract

Palmatine is a naturally occurring isoquinoline alkaloid with various pharmacological properties. Given its antioxidant and anti-inflammatory properties, palmatine may be able to impede the effects of metabolic syndrome (MetS) and its related diseases triggered by inflammation and oxidative stress. This review summarises the existing literature about the effects of palmatine supplementation on MetS and its complications. The evidence shows that palmatine could protect against MetS, and cardiovascular diseases, osteoporosis and osteoarthritis, which might be associated with MetS. These protective effects are mediated by the antioxidant and anti-inflammatory properties of palmatine. Although preclinical experiments have demonstrated the efficacy of palmatine against MetS and its related diseases, no human clinical trials have been performed to validate these effects. This research gap should be bridged to validate the efficacy and safety of palmatine supplementation in protecting humans against MetS and its related diseases.

Introduction

Metabolic syndrome (MetS) is a strong risk factor for type 2 diabetes, cardiovascular diseases and stroke, which carry high morbidity and threaten global health.Citation1 Although the definition of MetS has evolved with time, it is usually identified by the presence of 3 out of 5 metabolic anomalies, which include obesity, hyperglycaemia, dyslipidaemia [high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-c) and hypertension].Citation2,Citation3 Around 20–25% of the adult populations worldwide suffer from MetS.Citation4 Data from National Health and Nutrition Examination Survey between 2003 and 2012 revealed that the prevalence of MetS in the United States was 36.5% for women and 30.3% for men.Citation5 A systematic review reported that the incidence of MetS in the Asia-Pacific regions was between 11.9% and 37.1%.Citation6

Oxidative stress, characterised by an imbalance between oxidants and antioxidants in the body, plays a major role in the development of MetS.Citation7 Increased biomarkers of oxidative stress and diminished antioxidant defences were detected in the blood of patients with MetS, suggesting overproduction of oxidising agents in vivo.Citation8 This imbalance involved enzymatic [superoxide dismutase (SOD) activity] and non-enzymatic antioxidant defences (circulating vitamin C and E), as well as increased oxidation products of proteins and lipids.Citation8,Citation9 Increased adipose/fat tissue observed in obesity can trigger oxidative stress.Citation10 Tissue hypoxia due to the inadequate blood supply is a complication in obesity, which triggers cellular necrosis, and migration and phagocytosis of cellular debris by white blood cells.Citation11 The process will elevate oxidative stress due to the release of free radicals, such as nitric oxide and hydrogen peroxide, which may worsen the existing metabolic condition of the patients.Citation12Citation14 For example, blood pressure was positively associated with oxidative stress biomarkers and negatively associated with the antioxidant status of patients.Citation15 On the other hand, chronic inflammation instigated by a hyperactive immune response is another contributor to MetS.Citation16 Increased circulating pro-inflammatory cytokines, such as interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), were reported in patients with MetS.Citation17 These cytokines, produced by adipocytes and white blood cells, bind to the respective receptors on target cells and trigger a cascade of signalling events leading to adverse metabolic changes.Citation18

Natural compounds with anti-inflammatory and antioxidant properties, such as vitamin C, E and resveratrol, are hypothesised to prevent or reverse MetS complications.Citation19Citation21 Palmatine is one of the candidate agents being investigated for its anti-MetS properties. Palmatine is a naturally-occurring quaternary protoberberine in the class of isoquinoline alkaloids.Citation22,Citation23 Structurally, it is an ammonium salt with four methoxyl moieties attached to the phenyl rings at C2 and C3 position.Citation24 The preventive and curative actions of palmatine on cancer, cardiac hypertrophy, diabetes and its complications, osteoporosis, osteoarthritis, Alzheimer’s disease and atopic dermatitis have been reported.Citation24Citation26 The biological effects of palmatine could be attributed to its anti-inflammatoryCitation27Citation29 and antioxidant properties.Citation30Citation32 Of note, palmatine is shown to suppress Toll-like receptor (TLR) signalling by downregulating the expression of TLR4, Toll/IL-1 receptor-domain-containing adaptor protein inducing interferon-β and nuclear factor-kappa B in goat endometrial epithelial cells.Citation29 This event leads to increased synthesis of prostaglandins E2 and IL-10 but reduced synthesis of TNF-α, IL-1β, IL-6, nitric oxide, matrix metalloproteinase (MMP)-9 and MMP-2.Citation29 Therefore, the current review aims to summarise the effects of palmatine on MetS and its associated diseases.

The Effects of Palmatine on Components of MetS

Central obesity is a key feature of MetS. The excess nutrients are stored in the adipose tissue as lipids, leading to hypertrophy of adipocytes and increased fat mass.Citation33 Weight reduction through lifestyle, dietary, pharmacological and surgical interventions are often prescribed to patients with MetS.Citation34,Citation35 The antiadipogenic activities of palmatine have been demonstrated in in vitro and in vivo models. Choi et al reported that 3T3-L1 pre-adipocytes treated with palmatine (12.5, 25 and 50 µM) for 24 hrs showed reduced lipid accumulation compared to the untreated cells during differentiation.Citation36 Expression of proliferator-activated receptor-γ (PPAR-γ) and CCAAT/enhancer-binding protein-α (C/EBP-α) was also reduced with palmatine treatment, which signifies a reduction in adipogenesis. These positive findings justify further investigation into the anti-obesity effects of palmatine.

In an animal study by Ning et al, 4-week old Syrian golden hamsters with hyperlipidemia induced by with high-fat diet (HFD) showed reduced body weight, serum total cholesterol (TC), TG, and low-density lipoprotein cholesterol (LDL-c) after being treated with palmatine (23.35, 46.70 and 70.05 mg/kg/day) for four weeks.Citation37 Palmatine increased the expression of low-density lipoprotein receptor (LDLR) and cholesterol 7α-hydroxylase (CYP7A1), which mediate the endocytosis of cholesterol and the conversion of cholesterol to bile acid, respectively.Citation38Citation41 It also decreased apical sodium-dependent bile acid transporter (ASBT) mRNA and protein expression in these hamsters, which subsequently reduces the bile acid reabsorption in the intestine and increases the excretion of total bile acids in the faeces.Citation42,Citation43 Besides, CYP7A1 also will be upregulated to compensate for the low bile acid level by converting it to cholesterol.Citation44

Similarly, in another study by He et al, 5-week old Syrian golden hamsters with hyperlipidemia induced by high-fat high-cholesterol diet were treated with palmatine (46.7 mg/kg/day for 140 days).Citation45 The treated hamsters showed reduced body weight and epididymal adipose weight, improved lipid profile and increased LDLR and CYP7A1 mRNA and protein expression. Additionally, palmatine supplementation also reduced 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) mRNA and protein expression and increased uncoupling protein (UCP)-2 mRNA expressions.Citation45 HMGCR is the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol synthesis.Citation46 A decrease in HMGCR expression suggests a reduction in cholesterol production.Citation47,Citation48 UCP-2 is a mitochondrial protein involved in thermogenesis and energy expenditure.Citation49 An increase in UCP-2 expression is associated with a reduction in body weight due to improved energy metabolism.Citation50

In another study by Ma et al, female KK-Ay mice with hyperlipidemia and hyperglycemia induced by HFD showed a decrease in serum TC, TG and LDL-c but an increase in HDL-c after being treated with palmatine (25, 50, 100 mg/kg/day) for 40 days.Citation51 11-hydroxypalmatine (100 mg/kg/day) derived from tubers of Stephania glabra also reduced blood glucose level in alloxan-induced diabetic Swiss albino mice.Citation52 Palmatine (10 mg/kg for 6 weeks) also reduced blood glucose and increased insulin in streptozocin-induced diabetic rats.Citation32 These changes were attributed to reduced oxidative stress, marked by the lowering of malondialdehyde (MDA) and nitrite levels and the increasing of SOD activity.Citation32 However, 24 hrs of palmatine treatment (up to 14.6 µM) inhibited the glucose uptake in HepG2 cells via a non-concentration-dependent mannerCitation51 which suggest the hypoglycaemic properties of palmatine may not be related to glucose transportation or insulin sensitivity.

An overview of the effects of palmatine on components of MetS is presented in . Overall, palmatine supplementation attenuated the adverse effects associated with MetS. The cellular studies showed that palmatine could suppress the formation of adipocytes. Palmatine could also reduce cholesterol production and reabsorption, as well as enhancing energy metabolism, thereby improving lipid profile in animals. A general limitation for the in vivo studies is the absence of a positive control group, ie, pharmacological treatment for MetS. Therefore, the effects of palmatine and the standard treatment cannot be compared. Besides, clinical trial validating the effect of palmatine on MetS is absent in the literature. These research gaps should be considered in future studies.

Table 1 Protective Effect of Palmatine on MetS Components

The Effects of Palmatine on Cardiovascular Diseases Associated with MetS

MetS is a significant risk factor for myocardial infarction, a common obstructive heart disease and one of the leading causes of death in developed countries.Citation53 Apart from the pro-atherogenic environment, the pro-inflammatory and pro-oxidative conditions of MetS could damage the blood vessel wall, triggering coronary microvascular dysfunction.Citation54,Citation55 Insufficient supply of blood and oxygen to the heart is the initial cause of cardiac damage, thus an immediate blood supply restoration is crucial in minimising myocardial injury. However, sudden reperfusion causes tissue damage despite the restored blood flow, thereby worsening the initial ischemic injury.Citation56

The cardioprotective effects of palmatine have been reported in several studies. In a study by Kim et al, lipopolysaccharides (LPS)-stimulated RAW 264.7 cells treated with palmatine (1, 5, 10 µM for 16 hours) showed decreased high mobility group box 1 (HMGB1) release compared to the untreated LPS-stimulated cells.Citation31 HMGB1 regulates the activation of neutrophils during inflammation.Citation57 The reduction in HMGB1 by palmatine suggests that it could reduce inflammation during MI by lowering the influx of neutrophils into the dying tissues.Citation31 Human aortic endothelial cells (HAEC) treated with palmatine (1, 2, 5 and 10 µM for 8 hours) also showed increased heme oxygenase-1 (HO-1) with antioxidant and anti-inflammatory properties.Citation31 Together, these observations imply the potential effects of palmatine in reducing inflammatory damage to the myocardium during myocardial infarction.

In an animal study by Kim et al, male Sprague Dawley rats with ischemic reperfusion (I/R)-mediated acute myocardial infarction were treated with palmatine (25 and 50 mg/kg) 1 hr before ischemia.Citation31 Reduced MDA and increased SOD and catalase (CAT) activities suggestive of reduced oxidative stress were observed in I/R rats with palmatine treatment.Citation31 Palmatine treated I/R rats also showed reduced lactate dehydrogenase (LDH) and creatine phosphokinase (CK), which are intracellular metabolic enzymes of cardiomyocytes elevated after infarction.Citation31 Palmatine also increased the first derivative (±dp/dt) of left ventricular pressure and reduced infarct size of the heart.Citation31 In the myocardial tissues of I/R rats, cyclooxygenase-2 (COX-2) and inducible NO synthase (iNOS) expression were reduced with palmatine supplementation, suggestive of decreased inflammation in I/R-mediated myocardial infarction.Citation31

Taken together, palmatine is effective in reducing myocardial injury by suppressing inflammatory and oxidative damage associated with reperfusion in animal models. It could be used as an adjuvant to the standard therapy in the management of myocardial infarction. However, its putative use should be validated in a human clinical trial.

The Effects of Palmatine on Musculoskeletal Disorder Associated with MetS

Osteoporosis is a degenerative bone disease that can be triggered by low-grade inflammation and oxidative stress. Pro-inflammatory cytokines, such as TNF-α and IL-1, increase the production of receptor activator of nuclear factor-kB ligand (RANKL), which promote osteoclast formation and activation.Citation58,Citation59 They also suppress apoptosis and prolong the lifespan of osteoclasts.Citation60 Reactive oxygen species (ROS) trigger phosphorylation and degradation of nuclear factor-kappa B inhibitor, leading to the activation of nuclear factor-kappa B, thereby promoting osteoclast formation and activity.Citation61 ROS also induce apoptosis of osteoblasts by activating mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinases, c-Jun-N terminal kinase and p38.Citation62,Citation63 Altogether, these changes lead to altered bone remodelling favouring bone loss.

The simultaneous presence of inflammation and oxidative stress in MetS could potentially result in osteoporosis. The increase in adipocyte differentiation in bone marrow prevents osteoblast differentiation because they are derived from a common progenitor, the multipotential mesenchymal stem cells.Citation64 Adipose tissue is a significant source of pro-inflammatory cytokines which triggers bone resorption via mechanisms mentioned above.Citation65,Citation66 Products of lipid oxidation in dyslipidaemia induce oxidative stress on osteoblast and prevent their differentiation but activate PPAR-γ signalling and promote adipocyte differentiation.Citation16 In hypertension, competition between sodium and calcium ions reduces calcium reabsorption in the renal proximal tubule and contributes to increased urinary excretion of calcium.Citation16 In hyperglycaemia, the accumulation of advanced glycosylation end products (AGEs) in collagen could suppress bone remodelling and reduce bone quality, leading to increased fracture risk.Citation16,Citation67,Citation68

In a study by Ishikawa et al, palmatine (1, 5, 10, 40 and 100 μM for five days) decreased the number of osteoclasts formed from RAW 264.7 macrophages and bone resorption activity indicated by the reduction of total pit formation and fluorescent intensity of conditioned media.Citation69 Ishikawa et al also studied the effects of palmatine (1, 5, 10, 40, 100 and 200 μM for 3 days) on LPS-stimulated MC3T3-E1 pre-osteoblasts.Citation70 Palmatine decreased RANKL and osteoprotegerin (OPG) levels in culture supernatants of LPS-stimulated MC3T3-E1 pre-osteoblasts.Citation70 Similarly, the RANKL and OPG mRNAs expression of palmatine-treated pre-osteoblasts also reduced compared to untreated LPS-stimulated pre-osteoblasts.Citation70 In another study, RAW264.7 cells, mouse clonal stromal cells from bone marrow (ST2 cells), bone marrow cells (BMCs) and bone marrow macrophages (BMMs) were induced with RANKL or 1α,25-dihydroxyvitamin D3 to form osteoclasts followed by palmatine treatment (1, 10, 20 and 40µM) for 1 hr.Citation27 Palmatine lowered pit formation and actin ring formation in 1α,25-dihydroxyvitamin D3-treated BMC and ST2 co-culture.Citation27 RANKL (but not OPG and macrophage colony-stimulating factor) mRNA expression was also reduced upon palmatine treatment in 1α,25-dihydroxyvitamin D3-stimulated ST2 cells.Citation27,Citation71 Palmatine, however, did not significantly reduce the osteoclast formation in RANKL-treated BMMs.Citation27 Ishikawa et al validated the in vitro findings using ICR female mice with bilateral ovariectomy (OVX)-induced osteoporosis.Citation70 They were treated with 1 and 10 mg/kg/day of palmatine for 13 weeks.Citation70 The results showed that palmatine treatment reduced osteoclast number, serum RANKL, OPG and RANKL/OPG ratio in OVX-treated mice.Citation70 These results suggest that palmatine may be able to prevent osteoporosis by reducing bone turnover.Citation70 However, the effects of palmatine on bone in animal models of MetS have not been established. Further studies should consider validating the antiosteoporotic effects of palmatine using animal models induced by high-fat high-carbohydrate diet, which has been shown to induce deterioration of bone mass, structure and strength.Citation18,Citation20

Osteoarthritis is a degenerative joint disease marked by deterioration in articular cartilage, subchondral bone sclerosis and formation of osteophyte with significant clinical signs, such as chronic pain, joint instability, stiffness, and radiographic joint space narrowing.Citation72 In 2015, the World Health Organization estimated that 9.6% of people ≥60 years suffered from symptomatic osteoarthritis.Citation73 MetS is one of the primary risk factors of osteoarthritis, apart from age and joint injury.Citation74 Apart from increasing mechanical loading to the joint, obesity is associated with increased leptin production, which promotes inflammation and MMP synthesis.Citation75,Citation76 Cartilage degradation at the joint leads to localised inflammation and promote the further breakdown of cartilage through MMPs, forming a vicious cycle.Citation77

According to Zhou et al, IL-1β-activated proline chondrocytes treated with palmatine (10, 25, 50, and 100 mg/L for 6 hrs) showed decreased MMP-1, MMP-3, and MMP-13, and increased expression of tissue inhibitor of MMP (TIMP)-1, collagenase II, aggrecan and Dickkopf-related protein 1 (DKK-1).Citation78 These changes were attributable to decreased expression of β-catenin, glycogen synthase kinase-3β (GSK-3β), Indian hedgehog (Ihh), sonic hedgehog (Shh) and Gli-2 caused by palmatine treatment.Citation78 These effects of palmatine were found similar when chondrocytes co-treated with IL-1β and DKK-1 (the Wnt/β-catenin signalling inhibitor).Citation78 The co-incubation of cyclopamine (a Hedgehog signalling inhibitor) further enhanced the palmatine-mediated downregulation of GSK-3β, Ihh, Shh and Gli-2, suggestive the possibly inhibition of both Wnt/β-catenin and Hedgehog signalling pathways upon palmatine treatment.Citation78 These changes were validated by Zhou et al in an in vivo model, whereby decreased expressions of MMP-3, β-catenin, Ihh, Shh, Gli-2 and TNF-α with concomitant increased of TIMP-1 expression were observed in New Zealand rabbits with bilateral anterior cruciate ligament transections (ACLTs)-induced osteoarthritis and treated with palmatine (0.3 mL articular injection of 100 mg/L/week for five weeks).Citation78 Histologically, palmatine decreased erosion, osteophyte formation and cartilage degradation in the joints of the treated osteoarthritic rabbits.Citation78 These results suggest that palmatine may possess antiarthritic effects through reduction/inhibition of inflammatory mediators with the inhibition of Wnt/β-catenin and Hedgehog signalling pathways.Citation78 The effectiveness of palmatine on MetS-induced osteoarthritis model remains hypothetical due to the absence of animal models mimicking this process.

The detailed health benefits of palmatine have been summarised in . summarises the protective effects of palmatine on MetS and its associated diseases.

Table 2 Health Benefits of Palmatine Related to the Cardiovascular and Musculoskeletal System

Figure 1 The protective effects of palmatine on MetS and the associated diseases.

Abbreviations: ↓, decrease or downregulate; ↑, increase or upregulate; ┬, inhibit or suppress; AGEs, advanced glycosylation end products; ASBT, apical sodium-dependent bile acid transporter; CAT, catalase; COX, cyclooxygenase; C/EBP-α, CCAAT/enhancer-binding protein-α; HDL-c, high-density lipoprotein cholesterol; HFD, high fat diet; HMGB1, high mobility group box 1; HMGCR, 3-hydroxy-3-methyl glutaryl coenzyme A reductase; HO-1, heme oxygenase −1; iNOS, inducible NO synthase; Ihh, Indian hedgehog; LDL-c, low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor; MAPKs, mitogen-activated protein kinases; MI, myocardial infarction; MMP, matrix metalloproteinases; NFκB, nuclear factor kappa B; O2, oxygen; OA, osteoarthritis; OP, osteoporosis; OPG, osteoprotegerin; PAL, palmatine; PPAR-γ, proliferator-activated receptor-γ; RANKL, receptor activator of nuclear factor-kB ligand; Shh, Sonic hedgehog; SOD, superoxide dismutase; TG, triglyceride; TIMP-1, tissue inhibitors of metalloproteinases 1; TNF-α, tumor necrosis factor-α; UCP-2, uncoupling protein-2.
Figure 1 The protective effects of palmatine on MetS and the associated diseases.

Safety Evaluations of Palmatine

Similar to other isoquinoline alkaloids, palmatine can bind to DNA through groove-binding mechanism by forming hydrogen and van der Waals bonds.Citation79 Other studies demonstrated that palmatine binds to poly (A) and tRNA,Citation80,Citation81 adenine-thymine homo and hetero polymers through the intercalation.Citation82 It also binds preferentially to DNAs that have a long sequence of AT base pairs.Citation83 Besides, it exerts phototoxic effects by generating singlet molecular oxygen after forming complexes with DNA in water solution after photosensitization. The singlet molecular oxygen causes guanine photooxidation, and eventually cleavage of DNA structure.Citation84 These phenomena contribute to the anticancer activity of palmatine. As evidence, palmatine is reported to cause singlet oxygen generation and DNA fragmentation in human skin epithelial carcinoma cells in a dose- and time-depend manner.Citation85 Similar to cisplatin, a DNA-intercalating agent,Citation86 the mutagenic potential of palmatine can cause cellular damage in normal cells and induce secondary malignancy. However, this safety aspect of palmatine has not been explored using normal cells/animal models.

In a study by Yi et al, half-maximal inhibitory concentrations of palmatine on 3T3-L1 and HepG2 cells were 84.32 and 112.80 µg/mL, respectively.Citation87 An acute toxicity study showed a median lethal dose (LD50) of 1533.68 mg/kg in mice.Citation87 In the subchronic toxicity study, no irregularities in clinical signs, body and organ weight, haematological parameters, gross necropsy and histopathology were observed following oral administration of palmatine in rats (156 mg/kg; 5 female/5 male for 90 days).Citation87 All pharmacological studies reviewed in previous sections did not report mortality following palmatine supplementation.Citation87 Thus, palmatine is safe within the therapeutic range but this speculation needs to be validated in human studies. One of the highest doses used for MetS prevention in the reviewed studies is 100 mg/kg in mice.Citation51,Citation52 After translation using Reagan-Shaw formula,Citation88 this dose is equivalent to 486.5 mg for a 60-kg human, which is feasible for supplementation in humans.

Berberine, an isoquinoline alkaloid belonging to the same group as palmatine, has been demonstrated to have the potential to treat MetS and osteoporosis.Citation89Citation91 Comparison of the therapeutic potential between berberine and palmatine against MetS and its complications is limited, thus it is unsure which compound is more efficacious. In term of toxicity, the LD50 of berberine (oral administration) in mice is 329 mg/kg,Citation92 and a dose as low as 10 mg/kg (intraperitoneal administration) suppressed cellular and humoral immune functions in BALB/c mice.Citation93 Therefore, it could be more toxic than palmatine.

Palmatine is a substrate for P-glycoprotein (P-gp; an excretion transporter/efflux pump), but not for multidrug resistance-associated protein-2, which may justify its relative poor bioavailability.Citation94 Consequently, combining palmatine with P-gp substrates at this particular concentration range did not affect its intestinal absorption.Citation94,Citation95 In diabetic rats, the level of P-gp protein decrease in the small intestine, which could significantly improve palmatine’s intestinal permeability.Citation96,Citation97 This effect can help patients with insulin resistance in absorbing palmatine. However, delivering this drug in sufficient concentration to exert its systemic effects remains a challenge.

Conclusion

The evidence reviewed suggests that palmatine possesses therapeutic effect against MetS and its related disorders like cardiovascular disease, osteoporosis and osteoarthritis. Despite the generally positive effects derived from preclinical studies, there is a lack of human clinical trial to validate these findings. For this reason, well-planned human clinical trials should be conducted to bridge this research gap.

Disclosure

The authors report no conflicts of interest in this work.

Acknowledgments

We thank Universiti Kebangsaan Malaysia for funding the researchers through grant GUP-2020-021. Sophia Ogechi Ekeuku is a postdoctoral researcher funded by Faculty of Medicine, Universiti Kebangsaan Malaysia through FPR-1.

References

  • ChanKL, CathomasF, RussoSJ. Central and peripheral inflammation link metabolic syndrome and major depressive disorder. Physiology (Bethesda). 2019;34(2):123–133.30724127
  • WangHH, LeeDK, LiuM, PortincasaP, WangDQ. Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(3):189–230. doi:10.5223/pghn.2020.23.3.18932483543
  • ChinK-Y, WongSK, EkeukuSO, PangK-L. Relationship between metabolic syndrome and bone health – an evaluation of epidemiological studies and mechanisms involved. Diabetes Metab Syndr Obes. 2020;13:3667–3690.33116718
  • AlbertiKGMM, ZimmetP, ShawJ. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469–480. doi:10.1111/j.1464-5491.2006.01858.x16681555
  • AguilarM, BhuketT, TorresS, LiuB, WongRJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313(19):1973–1974. doi:10.1001/jama.2015.426025988468
  • RanasingheP, MathangasingheY, JayawardenaR, HillsAP, MisraA. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(1):101. doi:10.1186/s12889-017-4041-128109251
  • RobertsCK, SindhuKK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21–22):705–712. doi:10.1016/j.lfs.2009.02.02619281826
  • VonaR, GambardellaL, CittadiniC, StrafaceE, PietraforteD. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxid Med Cell Longev. 2019;2019:8267234. doi:10.1155/2019/826723431191805
  • SpahisS, BorysJM, LevyE. Metabolic syndrome as a multifaceted risk factor for oxidative stress. Antioxid Redox Signal. 2017;26(9):445–461. doi:10.1089/ars.2016.675627302002
  • MannaP, JainSK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;13(10):423–444. doi:10.1089/met.2015.009526569333
  • YeJ. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes. 2009;33(1):54–66. doi:10.1038/ijo.2008.229
  • BhattacharyaI, DominguezAP, DragertK, HumarR, HaasE, BattegayEJ. Hypoxia potentiates tumor necrosis factor-alpha induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in white and brown adipocytes. Biochem Biophys Res Commun. 2015;461(2):287–292. doi:10.1016/j.bbrc.2015.04.02025881506
  • KosackaJ, KernM, KlotingN, et al. Autophagy in adipose tissue of patients with obesity and type 2 diabetes. Mol Cell Endocrinol. 2015;409:21–32. doi:10.1016/j.mce.2015.03.01525818883
  • NetzerN, GattererH, FaulhaberM, BurtscherM, PramsohlerS, PestaD. Hypoxia, oxidative stress and fat. Biomolecules. 2015;5(2):1143–1150. doi:10.3390/biom502114326061760
  • MontezanoAC, Dulak-LisM, TsiropoulouS, HarveyA, BrionesAM, TouyzRM. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Can J Cardiol. 2015;31(5):631–641. doi:10.1016/j.cjca.2015.02.00825936489
  • WongSK, ChinK-Y, SuhaimiFH, AhmadF, JamilNA, Ima-NirwanaS. Osteoporosis is associated with metabolic syndrome induced by high-carbohydrate high-fat diet in a rat model. Biomed Pharmacother. 2018;98:191–200. doi:10.1016/j.biopha.2017.12.04229257979
  • BennettJM, ReevesG, BillmanGE, SturmbergJP. Inflammation-nature’s way to efficiently respond to all types of challenges: implications for understanding and managing “the epidemic” of chronic diseases. Front Med (Lausanne). 2018;5:316.30538987
  • WongSK, ChinKY, SuhaimiFH, AhmadF, Ima-NirwanaS. Effects of metabolic syndrome on bone mineral density, histomorphometry and remodelling markers in male rats. PLoS One. 2018;13(2):e0192416. doi:10.1371/journal.pone.019241629420594
  • de la IglesiaR, Loria-KohenV, ZuletMA, MartinezJA, RegleroG, Ramirez de MolinaA. Dietary strategies implicated in the prevention and treatment of metabolic syndrome. Int J Mol Sci. 2016;17(11):1877. doi:10.3390/ijms17111877
  • WongSK, ChinKY, SuhaimiFH, AhmadF, Ima-NirwanaS. The effects of Vitamin E from Elaeis guineensis (Oil Palm) in a rat model of bone loss due to metabolic syndrome. Int J Environ Res Public Health. 2018;15(9):1828. doi:10.3390/ijerph15091828
  • PangKL, ChinKY. The role of tocotrienol in protecting against metabolic diseases. Molecules. 2019;24(5):923. doi:10.3390/molecules24050923
  • LongJ, SongJ, ZhongL, LiaoY, LiuL, LiX. Palmatine: a review of its pharmacology, toxicity and pharmacokinetics. Biochimie. 2019;162:176–184. doi:10.1016/j.biochi.2019.04.00831051209
  • VrbaJ, PapouskovaB, PyszkovaM, et al. Metabolism of palmatine by human hepatocytes and recombinant cytochromes P450. J Pharm Biomed Anal. 2015;102:193–198. doi:10.1016/j.jpba.2014.09.01525285405
  • TarabaszD, Kukula-KochW. Palmatine: a review of pharmacological properties and pharmacokinetics. Phytother Res. 2020;34(1):33–50. doi:10.1002/ptr.650431496018
  • MengFC, WuZF, YinZQ, LinLG, WangR, ZhangQW. Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity. Chin Med. 2018;13:13. doi:10.1186/s13020-018-0171-329541156
  • RiosJL, FranciniF, SchinellaGR. Natural products for the treatment of type 2 diabetes mellitus. Planta Med. 2015;81(12–13):975–994. doi:10.1055/s-0035-154613126132858
  • LeeJ-W, MaseN, YonezawaT, et al. Palmatine attenuates osteoclast differentiation and function through inhibition of receptor activator of nuclear factor-kB ligand expression in osteoblast cells. Biol Pharm Bull. 2010;33(10):1733–1739. doi:10.1248/bpb.33.173320930384
  • WangL, WangX, ZhangSL, et al. Gastroprotective effect of palmatine against acetic acid-induced gastric ulcers in rats. J Nat Med. 2017;71(1):257–264. doi:10.1007/s11418-016-1057-227858308
  • YanB, WangD, DongS, et al. Palmatine inhibits TRIF-dependent NF-kappaB pathway against inflammation induced by LPS in goat endometrial epithelial cells. Int Immunopharmacol. 2017;45:194–200. doi:10.1016/j.intimp.2017.02.00428236763
  • KhaksariM, EsmailiS, AbedlooR, KhastarH. Palmatine ameliorates nephrotoxicity and hepatotoxicity induced by gentamicin in rats. Arch Physiol Biochem. 2019:1–6.
  • KimYM, HaYM, JinYC, et al. Palmatine from Coptidis rhizoma reduces ischemia-reperfusion-mediated acute myocardial injury in the rat. Food Chem Toxicol. 2009;47(8):2097–2102. doi:10.1016/j.fct.2009.05.03119497345
  • PaksereshtZ, NorouziP, HojatiV, MoghaddamKH. Effect of palmatine hydrochloride on oxidative stress in streptozotocin -induced diabetic rats. J Adv Med Biomed Res. 2016;24(107):119–129.
  • RamliNZ, ChinKY, ZarkasiKA, AhmadF. The beneficial effects of stingless bee honey from Heterotrigona itama against metabolic changes in rats fed with high-carbohydrate and high-fat diet. Int J Environ Res Public Health. 2019;16(24).
  • LiY, LeeS, LangleiteT, et al. Subsarcolemmal lipid droplet responses to a combined endurance and strength exercise intervention. Physiol Rep. 2014;2(11):e12187. doi:10.14814/phy2.1218725413318
  • MisraA, GuptaA, TankN, KaklotarD, SinghS, SharmaP Pharmacotherapy in metabolic syndrome; 2017:3.
  • ChoiJS, KimJH, AliMY, MinBS, KimGD, JungHA. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-alpha and PPAR-gamma. Fitoterapia. 2014;98:199–208. doi:10.1016/j.fitote.2014.08.00625128422
  • NingN, HeK, WangY, et al. Hypolipidemic effect and mechanism of palmatine from coptis chinensis in hamsters fed high-fat diet. Phytother Res. 2015;29(5):668–673. doi:10.1002/ptr.529525586479
  • ChenHY, YeXL, CuiXL, et al. Cytotoxicity and antihyperglycemic effect of minor constituents from Rhizoma Coptis in HepG2 cells. Fitoterapia. 2012;83(1):67–73. doi:10.1016/j.fitote.2011.09.01421968062
  • ChiangJY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50(10):1955–1966. doi:10.1194/jlr.R900010-JLR20019346330
  • HanH, XinP, ZhaoL, et al. Excess iodine and high-fat diet combination modulates lipid profile, thyroid hormone, and hepatic LDLr expression values in mice. Biol Trace Elem Res. 2012;147(1–3):233–239. doi:10.1007/s12011-011-9300-x22222482
  • ParkWH, PakYK. Insulin-dependent suppression of cholesterol 7alpha-hydroxylase is a possible link between glucose and cholesterol metabolisms. Exp Mol Med. 2011;43(10):571–579. doi:10.3858/emm.2011.43.10.06421817852
  • LanT, RaoA, HaywoodJ, KockND, DawsonPA. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism. J Hepatol. 2012;57(2):359–365. doi:10.1016/j.jhep.2012.03.02522542490
  • WaltersJR, TasleemAM, OmerOS, BrydonWG, DewT, le RouxCW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7(11):1189–1194. doi:10.1016/j.cgh.2009.04.02419426836
  • ChiangJYL, FerrellJM. Bile acid biology, pathophysiology, and therapeutics. Clin Liver Dis (Hoboken). 2020;15(3):91–94. doi:10.1002/cld.86132257118
  • HeK, KouS, ZouZ, et al. Hypolipidemic effects of alkaloids from rhizoma coptidis in diet-induced hyperlipidemic hamsters. Planta Med. 2016;82(8):690–697. doi:10.1055/s-0035-156826126848702
  • Wan HasanWN, ChinKY, Abd GhafarN, SoelaimanIN. Annatto-derived tocotrienol promotes mineralization of MC3T3-E1 cells by enhancing BMP-2 protein expression via inhibiting RhoA activation and HMG-CoA reductase gene expression. Drug Des Devel Ther. 2020;14:969–976. doi:10.2147/DDDT.S224941
  • HaererW, DelbaereK, BartlettH, LordSR, RowlandJ. Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. Intern Med J. 2012;42(12):1329–1334. doi:10.1111/j.1445-5994.2011.02622.x22032261
  • NotarnicolaM, MessaC, RefoloMG, TutinoV, MiccolisA, CarusoMG. Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Lipids Health Dis. 2010;9:135. doi:10.1186/1476-511X-9-13521118482
  • BrondaniLA, AssmannTS, de SouzaBM, BoucasAP, CananiLH, CrispimD. Meta-analysis reveals the association of common variants in the uncoupling protein (UCP) 1-3 genes with body mass index variability. PLoS One. 2014;9(5):e96411. doi:10.1371/journal.pone.009641124804925
  • OhKS, KimM, LeeJ, et al. Liver PPARalpha and UCP2 are involved in the regulation of obesity and lipid metabolism by swim training in genetically obese db/db mice. Biochem Biophys Res Commun. 2006;345(3):1232–1239. doi:10.1016/j.bbrc.2006.04.18216716264
  • MaH, HuY, ZouZ, FengM, YeX, LiX. Antihyperglycemia and antihyperlipidemia effect of protoberberine alkaloids from rhizoma coptidis in HepG2 cell and diabetic KK-Ay mice. Drug Dev Res. 2016;77(4):163–170. doi:10.1002/ddr.2130227045983
  • SemwalDK, RawatU, SemwalR, SinghR, SinghGJ. Anti-hyperglycemic effect of 11-hydroxypalmatine, a palmatine derivative from Stephania glabra tubers. J Asian Nat Prod Res. 2010;12(2):99–105. doi:10.1080/1028602090311732520390750
  • KhademvatanK, AlinejadV, EghtedarS, RahbarN, AgakhaniN. Survey of the relationship between metabolic syndrome and myocardial infarction in hospitals of Urmia University of medical sciences. Glob J Health Sci. 2014;6(7 Spec No):58–65. doi:10.5539/gjhs.v6n7p5825363180
  • MaedaK, RuelM. Prevention of ischemia-reperfusion injury in cardiac surgery: therapeutic strategies targeting signaling pathways. J Thorac Cardiovasc Surg. 2015;149(3):910–911. doi:10.1016/j.jtcvs.2014.11.06725534485
  • Monserrat-MesquidaM, Quetglas-LlabresM, CapoX, et al. Metabolic syndrome is associated with oxidative stress and proinflammatory state. Antioxidants (Basel). 2020;9(3).
  • SchanzeN, BodeC, DuerschmiedD. Platelet contributions to myocardial ischemia/reperfusion injury. Front Immunol. 2019;10:1260. doi:10.3389/fimmu.2019.0126031244834
  • ParkJS, ArcaroliJ, YumHK, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003;284(4):C870–C879. doi:10.1152/ajpcell.00322.200212620891
  • AmarasekaraDS, YunH, KimS, LeeN, KimH, RhoJ. Regulation of osteoclast differentiation by cytokine networks. Immune Netw. 2018;18(1):e8. doi:10.4110/in.2018.18.e829503739
  • LuoG, LiF, LiX, WangZG, ZhangB. TNFalpha and RANKL promote osteoclastogenesis by upregulating RANK via the NFkappaB pathway. Mol Med Rep. 2018;17(5):6605–6611.29512766
  • SoysaNS, AllesN. Positive and negative regulators of osteoclast apoptosis. Bone Rep. 2019;11:100225. doi:10.1016/j.bonr.2019.10022531720316
  • CallawayDA, JiangJX. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab. 2015;33(4):359–370. doi:10.1007/s00774-015-0656-425804315
  • FontaniF, MarcucciG, IantomasiT, BrandiML, VincenziniMT. Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling. Calcif Tissue Int. 2015;96(4):335–346. doi:10.1007/s00223-015-9961-025660312
  • MaratheN, RangaswamiH, ZhuangS, BossGR, PilzRB. Pro-survival effects of 17beta-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J Biol Chem. 2012;287(2):978–988. doi:10.1074/jbc.M111.29495922117068
  • HaladeGV, RahmanMM, WilliamsPJ, FernandesG. High fat diet-induced animal model of age-associated obesity and osteoporosis. J Nutr Biochem. 2010;21(12):1162–1169. doi:10.1016/j.jnutbio.2009.10.00220149618
  • CalderPC, AhluwaliaN, BrounsF, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr. 2011;106(Suppl 3):S5–S78. doi:10.1017/S000711451100546022133051
  • CamposRM, de PianoA, da SilvaPL, et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine. 2012;42(1):146–156. doi:10.1007/s12020-012-9613-322315014
  • ChinKY, Ima-NirwanaS, MohamedIN, et al. Insulin-like growth factor-1 is a mediator of age-related decline of bone health status in men. Aging Male. 2014;17(2):102–106. doi:10.3109/13685538.2014.89689524593848
  • JackuliakP, PayerJ. Osteoporosis, fractures, and diabetes. Int J Endocrinol. 2014;2014:820615.25050121
  • IshikawaS, TamakiM, OgawaY, et al. Inductive effect of palmatine on apoptosis in RAW 264.7 cells. Evid Based Complement Alternat Med. 2016;2016:7262054. doi:10.1155/2016/726205427340419
  • IshikawaS, OgawaY, TamakiM, et al. Influence of palmatine on bone metabolism in ovariectomized mice and cytokine secretion of osteoblasts. In Vivo. 2015;29(6):671–677.26546523
  • LeeWC, KimJK, KangJW, et al. Palmatine attenuates D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice. Food Chem Toxicol. 2010;48(1):222–228. doi:10.1016/j.fct.2009.10.00419818826
  • WangM, ShenJ, JinH, ImHJ, SandyJ, ChenD. Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci. 2011;1240:61–69. doi:10.1111/j.1749-6632.2011.06258.x22172041
  • World Health Organization. Chronic rheumatic conditions; 2020 Available from: https://www.who.int/chp/topics/rheumatic/en/. Accessed 820, 2020.
  • BucheleG, GuntherKP, BrennerH, et al. Osteoarthritis-patterns, cardio-metabolic risk factors and risk of all-cause mortality: 20 years follow-up in patients after hip or knee replacement. Sci Rep. 2018;8(1):5253. doi:10.1038/s41598-018-23573-229588472
  • OztasB, SahinD, KirH, et al. The effect of leptin, ghrelin, and neuropeptide-Y on serum Tnf-Alpha, Il-1beta, Il-6, Fgf-2, galanin levels and oxidative stress in an experimental generalized convulsive seizure model. Neuropeptides. 2017;61:31–37. doi:10.1016/j.npep.2016.08.00227522536
  • WilliamsRC, SkeltonAJ, TodrykSM, RowanAD, PreshawPM, TaylorJJ. Leptin and pro-inflammatory stimuli synergistically upregulate MMP-1 and MMP-3 secretion in human gingival fibroblasts. PLoS One. 2016;11(2):e0148024. doi:10.1371/journal.pone.014802426829555
  • BerenbaumF. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(1):16–21. doi:10.1016/j.joca.2012.11.01223194896
  • ZhouX, LinX, XiongY, et al. Chondroprotective effects of palmatine on osteoarthritis in vivo and in vitro: a possible mechanism of inhibiting the Wnt/beta-catenin and Hedgehog signaling pathways. Int Immunopharmacol. 2016;34:129–138. doi:10.1016/j.intimp.2016.02.02926945831
  • MiR, TuB, BaiXT, ChenJ, OuyangY, HuYJ. Binding properties of palmatine to DNA: spectroscopic and molecular modeling investigations. Luminescence. 2015;30(8):1344–1351. doi:10.1002/bio.290425829078
  • IslamMM, PandyaP, ChowdhurySR, KumarS, KumarGS. Binding of DNA-binding alkaloids berberine and palmatine to tRNA and comparison to ethidium: spectroscopic and molecular modeling studies. J Mol Struct. 2008;891(1):498–507. doi:10.1016/j.molstruc.2008.04.043
  • GiriP, HossainM, KumarGS. Molecular aspects on the specific interaction of cytotoxic plant alkaloid palmatine to poly(A). Int J Biol Macromol. 2006;39(4):210–221.16678250
  • BhadraK, MaitiM, KumarGS. Molecular recognition of DNA by small molecules: AT base pair specific intercalative binding of cytotoxic plant alkaloid palmatine. Biochim Biophys Acta. 2007;1770(7):1071–1080. doi:10.1016/j.bbagen.2007.03.00117434677
  • BhadraK, MaitiM, KumarGS. Interaction of isoquinoline alkaloid palmatine with deoxyribonucleic acids: binding heterogeneity, and conformational and thermodynamic aspects. Chem Biodivers. 2008;5(4):575–590.18421749
  • HirakawaK, KawanishiS, HiranoT. The mechanism of guanine specific photooxidation in the presence of berberine and palmatine: activation of photosensitized singlet oxygen generation through DNA-binding interaction. Chem Res Toxicol. 2005;18(10):1545–1552. doi:10.1021/tx050174016533018
  • AliD, AliH. Assessment of DNA damage and cytotoxicity of palmatine on human skin epithelial carcinoma cells. Toxicol Environ Chem. 2014;96(6):941–950. doi:10.1080/02772248.2014.987510
  • FungC, DinhP, Ardeshir-Rouhani-FardS, SchafferK, FossaSD, TravisLB. Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors. Adv Urol. 2018;2018:8671832. doi:10.1155/2018/867183229670654
  • YiJ, YeX, WangD, et al. Safety evaluation of main alkaloids from Rhizoma Coptidis. J Ethnopharmacol. 2013;145(1):303–310. doi:10.1016/j.jep.2012.10.06223159469
  • Reagan-ShawS, NihalM, AhmadN. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–661. doi:10.1096/fj.07-9574LSF17942826
  • WongSK, ChinK-Y, Ima-NirwanaS. Berberine and musculoskeletal disorders: the therapeutic potential and underlying molecular mechanisms. Phytomedicine. 2020;73:152892.30902523
  • CaoC, SuM. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med. 2019;17(4):3009–3014.30936971
  • HuX, ZhangY, XueY, ZhangZ, WangJ. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Am J Transl Res. 2018;10(11):3322–3329.30662589
  • SinghN, SharmaB. Toxicological effects of berberine and sanguinarine. Front Mol Biosci. 2018;5:21. doi:10.3389/fmolb.2018.0002129616225
  • MahmoudiM, Zamani Taghizadeh RabeS, Balali-MoodM, et al. Immunotoxicity induced in mice by subacute exposure to berberine. J Immunotoxicol. 2016;13(2):255–262. doi:10.3109/1547691X.2015.105830626100397
  • ZhangX, QiuF, JiangJ, GaoC, TanY. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica. 2011;41(4):290–296. doi:10.3109/00498254.2010.52918021319959
  • YuCP, HuangCY, LinSP, HouYC. Activation of P-glycoprotein and CYP 3A by coptidis rhizoma in vivo: using cyclosporine as a probe substrate in rats. J Food Drug Anal. 2018;26(2S):S125–S132. doi:10.1016/j.jfda.2017.11.00529703381
  • KoboriT, HaradaS, NakamotoK, TokuyamaS. Functional alterations of intestinal P-glycoprotein under diabetic conditions. Biol Pharm Bull. 2013;36(9):1381–1390. doi:10.1248/bpb.b13-0036923995645
  • NeeartiP, BarlaR, BedadaSK. Influence of diabetes mellitus on P-glycoprotein function in rat intestine. Pharmacologia. 2011;2:293–298. doi:10.5567/pharmacologia.2011.293.298